AdoRx Therapeutics, a UK based drug discovery company focused on the identification of new cancer therapeutics, today announced that it has closed an initial $10 million investment round financed by Epidarex Capital and CRT Pioneer Fund (‘CPF’).

Micrima, the Bristol-based breast imaging company, has raised £4.4 million in additional equity funding led by Technology Venture Partners, The Angel CoFund (ACF), and Venture Founders - plus a group of returning and new individual investors - bringing the total amount raised to £10.7m.

Roy Johnson, Micrima’s Executive Chairman, said, “I am very happy to announce the completion of our latest funding round, which provides us with the capital we need to move our initial MARIA product into full commercial launch and follow this swiftly with the enhanced functionality that the system is capable of achieving. The market has been prepared over the past 18 months through the publication of our historical clinical trial data, and attendance at numerous congresses and trade shows to showcase our breakthrough technology. As a result, we have many influential clinicians and partners anticipating the launch of MARIA later this year. We look forward to putting the product we have worked so hard to create into their hands for the first time.”

Healios, the digital therapy company for mental health, has raised £2.2m ($3m) in its latest funding round, led by investors Albion Capital and Spice Capital.

Catalan biomedical companies attracted €102 million in investment in 2017, with €3.4 million per operation, on average. This will allow them to push forward in the development of drugs and innovative medical technology, as reflected in the Study on investment in the Biomedical industry in Catalonia: Achievements and future challenges presented today by CataloniaBio & HealthTech and EY  in Barcelona. The event drew a crowd of more than 60 entrepreneurs, investors and professionals from the sector.

Zebra Medical Vision, the leading machine and deep learning startup, is announcing today it has raised $30M in C round funding, bringing the total investment in the company to $50M. In addition, the company is unveiling its Textray chest x-ray research today, the most comprehensive AI research conducted on chest x-rays to date, which provides a glimpse into a future automated chest x-ray analysis product being developed by the company.

MediSieve Ltd, the team behind an innovative blood filtration device, are happy to announce the company has received over £1.75 million in funding.

The cash influx has come from a mix of both old and new investors – reflecting the growing confidence in the potential of the device. The medical device company is best known for their magnetic blood filtration technology, a revolutionary new approach to targeting blood-borne diseases by magnetically filtering specific disease-causing components from the bloodstream. The device is being tested for the treatment of Malaria, Sepsis and Leukaemia.

Technology-enabled homecare start-up Cera has raised $17m in Series A funding, just a year and half after launching. 

NVM Private Equity has invested £1.0 million of growth capital into Cambridge-based medical device company Ablatus Therapeutics Limited (“Ablatus”) alongside existing angel investors.

TxCell SA, a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces it will present its latest manufacturing developments at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress to be held in Frankfurt, Germany, on May 29-30, 2018. 

Digital healthcare provider MedicSpot has received investment from a member of Henley Business Angels as part of the SEIS qualifying fund raise. In total MedicSpot is raising £1m in funding and has rapidly closed its oversubscribed £150k SEIS round.

Spherium Biomed has disclosed the top line results of its Phase II clinical trial of Mucomel®, an oral gel for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing chemo/bio-radiotherapy.

Calculus Capital has completed a further investment into a growth capital investment round for Mologic alongside Foresight Group, who led the round.